Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ideaya Biosciences Inc (IDYA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: IDYA (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 53.86% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49B USD | Price to earnings Ratio - | 1Y Target Price 52.71 |
Price to earnings Ratio - | 1Y Target Price 52.71 | ||
Volume (30-day avg) 992162 | Beta 0.75 | 52 Weeks Range 14.39 - 44.42 | Updated Date 03/31/2025 |
52 Weeks Range 14.39 - 44.42 | Updated Date 03/31/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2059.11% |
Management Effectiveness
Return on Assets (TTM) -23.05% | Return on Equity (TTM) -32.67% |
Valuation
Trailing PE - | Forward PE 4.65 | Enterprise Value 774963716 | Price to Sales(TTM) 184.7 |
Enterprise Value 774963716 | Price to Sales(TTM) 184.7 | ||
Enterprise Value to Revenue 110.71 | Enterprise Value to EBITDA -7.8 | Shares Outstanding 87537400 | Shares Floating 86629628 |
Shares Outstanding 87537400 | Shares Floating 86629628 | ||
Percent Insiders 1.04 | Percent Institutions 109.51 |
Analyst Ratings
Rating 4.71 | Target Price 55.71 | Buy 2 | Strong Buy 11 |
Buy 2 | Strong Buy 11 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ideaya Biosciences Inc
Company Overview
History and Background
Ideaya Biosciences Inc. was founded in 2010. It is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
Core Business Areas
- Synthetic Lethality: Focuses on identifying and developing therapies that exploit vulnerabilities in cancer cells arising from specific genetic mutations.
- Protein Kinase Inhibitors: Developing small molecule inhibitors targeting protein kinases involved in cancer cell growth and survival.
- DNA Damage Response (DDR): Develops therapeutics that target mutations in DNA Damage Response (DDR) pathways.
Leadership and Structure
Darren G. Burdett, PhD serves as President and CEO. The company has a board of directors and operates with a functional organizational structure focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- IDE196 (PKC Inhibitor): A protein kinase C (PKC) inhibitor being developed for genetically defined cancers, including those with GNAQ/11 mutations. Phase 2 clinical trials are underway. Competitors include companies developing other PKC inhibitors or alternative therapies for these cancers.
- IDE397 (MAT2A Inhibitor): A methionine adenosyltransferase 2A (MAT2A) inhibitor targeting cancers with MTAP deletions. Phase 1/2 clinical trials are ongoing. Competitors include other companies developing MAT2A inhibitors or targeting MTAP-deleted cancers through other mechanisms.
- PARP Inhibitor (Collaboration with GSK): Ideaya has a PARP inhibitor program under development in collaboration with GSK, targeting tumors with homologous recombination deficiency (HRD). Competitors include AZN's Lynparza, and other established PARP inhibitors.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and growing, driven by increasing cancer incidence and advancements in personalized medicine. The focus is on precision medicine and targeted therapies.
Positioning
Ideaya is positioned as a precision medicine company focused on synthetic lethality and other novel targets. Its competitive advantage lies in its discovery platform and focus on genetically defined patient populations.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics is estimated to be in the hundreds of billions of dollars. Ideaya is targeting specific subsets of this market, focusing on genetically defined cancers. The TAM specific to their pipeline is still substantial and will be realized as they develop through phases.
Upturn SWOT Analysis
Strengths
- Strong discovery platform
- Focus on precision medicine and targeted therapies
- Strategic collaborations with major pharmaceutical companies (e.g., GSK)
- Experienced management team
- Novel pipeline candidates
Weaknesses
- Clinical trial risks and uncertainties
- High cash burn rate typical of biotech companies
- Reliance on collaborations for funding and development
- Limited commercialization experience (as of now)
Opportunities
- Expansion of pipeline through internal discovery and collaborations
- Advancement of clinical programs to commercialization
- Potential for partnerships and licensing agreements
- Growing demand for precision medicine therapies
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles and clinical trial failures
- Changes in reimbursement policies
- Patent expiration and generic competition
Competitors and Market Share
Key Competitors
- AZN
- MRTX
- GILD
Competitive Landscape
Ideaya competes with larger pharmaceutical companies and other biotech companies in the oncology space. Its competitive advantage lies in its focus on precision medicine and novel targets, but it faces challenges in terms of resources and commercialization capabilities.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Ideaya's growth is driven by the advancement of its pipeline and strategic collaborations.
Future Projections: Analyst estimates vary, but generally project growth driven by the successful development and commercialization of its pipeline candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for IDE196 and IDE397, and expanding its collaboration with GSK.
Summary
Ideaya Biosciences is a precision medicine company with a promising pipeline and strategic collaborations. The company's focus on synthetic lethality and targeted therapies offers potential for growth, but faces risks associated with clinical trials and competition from larger pharmaceutical companies. Successful development of their pipeline and expansion of partnerships is needed to maintain long-term growth. Investors should carefully assess the company's financial position and clinical trial outcomes.
Similar Companies
- AZN
- MRTX
- GILD
- GSK
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share is approximate and based on available data.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ideaya Biosciences Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2019-05-23 | President, CEO & Director Mr. Yujiro S. Hata | ||
Sector Healthcare | Industry Biotechnology | Full time employees 131 | Website https://www.ideayabio.com |
Full time employees 131 | Website https://www.ideayabio.com | ||
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung (SCLC) and MTAP-deletion urothelial cancer; IDE849, a DLL3 antibody drug conjugate inhibitor that is in Phase 1 clinical trial for the treatment of SCLC and neuroendocrine tumors; IDE275, a Werner Helicase inhibitor that is in Phase 1 clinical trial for patients having tumors with high microsatellite instability; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1/2 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD. It also develops preclinical programs, including IDE892, a MTA-cooperative PRMT5 inhibitor; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; and IDE251, a KAT6/7 inhibitor. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Merck, Biocytogen, Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.